Articles tagged with Melanoma
Younger patients with resected melanoma showed a benefit from adjuvant bevacizumab treatment, while older patients did not. The study suggests that sFRP2 may promote angiogenesis in older patients with melanoma, which is superseding the role of VEGF.
A key blood marker of cancer could be used to select the most effective treatment for melanoma, according to an Edith Cowan University study. The discovery has the potential to improve melanoma survival rates by identifying patients who may benefit from more aggressive treatments.
A new study has discovered that accumulated DNA damage in skin cells can be used to estimate the risk of deadly skin cancer. Researchers sequenced DNA from individual melanocytes and found a significant number of mutations associated with melanoma, even in people without visible moles.
Researchers found people with pale-colored melanomas are more likely to have an albinism gene mutation, which prevents brown pigment synthesis and increases skin cancer risk. This discovery could lead to personalized medicine and earlier treatment for patients with one mutated albinism gene.
People with pale-colored melanomas are more susceptible to developing rare genetic mutations associated with albinism. Researchers plan to collect samples to compare genotype and develop personalized monitoring for patients with one albinism gene mutation.
A collaborative study has uncovered new markers uniquely present on melanoma tumours that can be recognised by the immune system. These markers, known as spliced peptides, can be used to develop therapeutic vaccines to combat melanoma.
Scientists have discovered a rapid, inexpensive, and non-invasive method to track malignant melanoma using fluorescent molecules in urine samples. The technique allows doctors to diagnose and monitor the disease without requiring invasive biopsies.
A consensus statement evaluates the use of prognostic genetic expression profile testing in melanoma, cautioning against routine use due to limitations. The statement aims to assist clinicians in determining when and how gene expression profiling should be adopted in clinical practice.
Scientists at Sanford Burnham Prebys discovered that PRMT5 inhibitors can sensitize unresponsive melanoma to immune checkpoint therapy, enhancing antigen presentation and innate immunity. The study suggests that these inhibitors may also be effective in tumors of other types, providing a potential breakthrough for cancer treatment.
This study defines the mutation profile of SUM in Caucasians using next-generation sequencing-based genomic analysis, identifying frequently mutated genes. The most abundant mutations were found in KIT and NRAS, while BRAF was only present in 3% of cases, providing insights into the genetics of subungual melanoma.
A study of 34,000 biologic-treated patients found an increased melanoma risk compared to 135,000 conventional therapy patients. The results suggest a potential association between long-term use of biologics for inflammatory diseases and the development of melanoma.
Scientists have identified two genes responsible for a melanoma that develops near the tails of male highland-sheepshead hybrids. These findings provide insight into the genetic causes of hybrid dysfunction and its effects on disease, highlighting the importance of understanding gene interactions in different species.
Researchers found improved survival among patients with malignant melanoma who used desloratadine and loratadine, particularly in the age group 65 and older. The study suggests these antihistamines may also reduce the risk of new malignant melanoma cases.
Prolgolimab, a Russian original PD-1 inhibitor, has been approved for the treatment of advanced melanoma. The drug demonstrated significant antitumor activity and manageable safety in a phase II study, with 42 out of 126 patients experiencing an objective response.
Researchers identified 33 new regions and confirmed 21 previously reported regions linked to melanoma risk, shedding light on the immune system's role in the disease. The study also uncovered associations between melanoma and common genetic variants in the TP53 gene.
Researchers developed an AI algorithm that can classify cutaneous skin disorders, predict malignancy, and suggest primary treatment options. The algorithm improved the diagnostic accuracy of clinicians, including dermatologists and the general public, by up to 86.8%.
Death rates from metastatic melanoma dropped by nearly 18 percent between 2013 and 2016, thanks to new therapies that harness the immune system or target specific gene mutations. These advances in treatment have led to the largest yearly declines in deaths due to melanoma ever recorded.
A recent study funded by the European Academy of Dermatology and Venereology found a potential link between partner bereavement and skin cancer. Researchers discovered that individuals who experienced the loss of a partner had a decreased risk of being diagnosed with melanoma, but an increased risk of dying after diagnosis.
Research published in the British Journal of Dermatology found that bereaved individuals have a 17% higher risk of dying from melanoma compared to non-bereaved persons. Those who had lost a partner were also 12% less likely to be diagnosed with melanoma, highlighting the importance of skin checks for early detection and improved survival.
A pilot study by researchers at the University of Cincinnati shows that radiation therapy before immunotherapy may increase patient survival for those with brain metastases. The combination therapy was found to be superior to radiation alone, with genes associated with cell death signaling and inflammation present in tissue.
A new study reveals wide state-by-state variation in melanoma rates attributed to ultraviolet radiation, with highest rates found on the East and West Coasts. States like Hawaii, Utah, Vermont, and Minnesota have high UV-attributable incidence rates, likely due to outdoor activities and sun protection.
A review of evidence published in The BMJ found that smartphone apps assessing mole risk cannot detect all skin cancers. While AI-powered apps offer potential for earlier detection and treatment, limitations and variable performance indicate insufficient promise to recommend their use.
Researchers found improved survival times of 13.6 months and 17.8 months for uveal melanoma patients with liver metastasis treated with new therapies, compared to 5.3 months in earlier years. The shift from systemic chemotherapy to targeted liver treatments has led to significant benefits.
A study published in Clinical Cancer Research found that circulating tumor cells were associated with a decrease in relapse-free survival at six months, and this association persisted at a 54-month longer-term follow-up. This suggests that CTC assessment may be useful in identifying patients at risk for relapse who could benefit from m...
Isolated limb infusion (ILI) is a new method for treating melanoma metastases confined to an extremity, offering a more targeted and less exhausting alternative to systemic chemotherapy. The study found an overall response rate of 76% and long-term limb salvage rate of 90%, comparable to high-volume centers in the US and Australia.
Researchers developed a new technique to predict which primary melanoma patients are at risk for cancer recurrence and spread by analyzing T-cell fraction in skin lesions. Patients with lower T-cell fraction (less than 20%) were found to be 2.5 times more likely to have cancer metastasize.
Researchers at University of Bath identified a molecule called DIRC3 that acts as a tumour suppressor to block melanoma cell growth and spread. High levels of DIRC3 expression in patients were linked to increased survival rates, suggesting its potential as a new treatment for skin cancer.
A study at UT Southwestern Medical Center found that patients who received Mohs surgery for melanoma reported a 95% long-term satisfaction rate with their results. The highly precise excision technique resulted in minimal scarring and a nearly 99% cure rate for early melanoma.
A study found that popular gym chains offer tanning beds in over 78% of their locations, despite public health warnings about the dangers of indoor tanning. Gyms are undermining health by marketing tanning beds to physically active people who are at increased risk for melanoma.
Prof. Carmit Levy receives Young Investigator Award from SMR for her significant contributions to melanoma research, discovering key elements of metastasis and laying groundwork for future therapies.
Researchers at University of Queensland have discovered markers in blood that differentiate benign moles from melanoma, as well as detect cancer spread to other areas. The blood test may monitor very early signs of the disease, allowing for better screening of patients with eye naevi.
A study analyzing US melanoma data found a decline in adolescent and young adult cases between 2006 and 2015, while older adults experienced an increase in melanoma rates during the same period. The research used registry data to determine age-specific annual rates of melanoma.
Cases of melanoma declined among US adolescents and young adults from 2006 to 2015, with incidence rates dropping by 4% per year for males and 4.5% per year for females in the two age groups. Public health efforts advocating sun protection may be contributing to this trend.
Researchers investigated weight loss surgery and skin cancer risk among 4,000 Swedish patients. The study found a significant association between the two, suggesting that weight loss surgery may reduce skin cancer risk.
Researchers developed a new approach to diagnosing melanoma using microRNA biomarkers, achieving high sensitivity and specificity rates. The method overcomes challenges of tumor heterogeneity and improves diagnostic accuracy, potentially leading to earlier detection and better patient outcomes.
A combination of ipilimumab and nivolumab has stopped or reversed melanoma progression for five years in nearly half of patients, offering new hope for advanced melanoma patients. The Checkmate 067 trial found a 52% five-year overall survival rate, with 74% treatment-free after five years.
Researchers found that combination immunotherapy increases the 5-year overall survival rate to 52%, compared to 26% for ipilimumab monotherapy, and preserves quality of life. The therapy has a high cure rate and is effective even in patients who stop treatment due to side effects.
Researchers have identified a combination therapy of MDM2 compounds and CDK4/6 inhibitors as a possible solution for overcoming resistance to these drugs in melanoma patients. The therapy was shown to reverse resistance mechanisms in multiple mouse models and human tumor slice culture assays.
Researchers at the University of Queensland have identified specific gene variations that affect mole patterns and melanoma risk. By studying the number and types of moles on the body, doctors can provide more holistic care to patients who may be at risk of developing melanoma.
A recent study published in Pigment Cell & Melanoma Research has found that genetic factors significantly influence not only the number of moles but also their location on the body. In women, the largest genetic impact is seen on the lower limbs, with a higher concentration of moles in this area compared to men.
Researchers at Tel Aviv University have developed a novel nano-vaccine for melanoma, which has proven effective in preventing the development of melanoma in mouse models and treating primary tumors. The vaccine uses nanoparticles to stimulate the immune system and attack cancer cells.
A new study found that genetic testing motivates people at risk of developing melanoma to change their behavior, including reducing sun exposure. Participants who received genetic counseling showed sustained reductions in UV radiation exposure and lighter skin pigmentation over time.
Research suggests that primary care physicians trained in dermatoscopy can detect melanoma earlier and more accurately, reducing the need for invasive biopsies. The study found that a dermatoscope can improve diagnosis by four times compared to unaided eye inspection.
A study of nearly 57,000 patients found that those with multiple primary melanomas had a significantly lower survival rate. Patients with multiple primary melanomas were more likely to die from the disease compared to those with a single primary melanoma.
A UCLA-led research team has pinpointed a three-drug combination that can effectively treat advanced melanoma. The approach shows promise for extending the lives of people with BRAF V600E mutated melanoma, with progression-free survival lasting an average of 16 months.
Melanoma is a type of skin cancer linked to sun exposure, with common areas affected including face, neck, arms, and torso. Genomic sequencing helps identify markers for diagnosis and treatment, while ABCDE criteria aid in suspicious lesion detection.
Researchers investigated risk factors for melanoma dissemination and the impact of time on distant relapse. The findings provide valuable information for improving melanoma treatment outcomes.
Researchers at CNIO have discovered biomarkers in surgically treated patients' fluid that reveal specific mutations and help determine cancer recurrence risk. The new liquid biopsy technique may enable earlier detection and more targeted treatment for melanoma patients.
A University of Colorado Cancer Center study identifies a possible way to predict which melanomas are hot and cold for immunotherapy. Tumors with specific genetic changes in the NF-kB signaling pathway are more likely to respond to anti-PD1 immunotherapies, suggesting a potential biomarker for treatment prediction.
Researchers have discovered a causal link between the gut microbiome and anti-tumor immunity, identifying key bacterial strains that activate the immune system to slow melanoma growth. The study also reveals the role of unfolded protein response (UPR) in this process, providing potential markers for patient stratification.
Researchers found a promising lead in seriniquone, a natural product isolated from seawater bacteria, to treat melanoma. The compound targets a specific biochemical pathway in melanoma cells and has shown potent activity against the disease.
PET/CT scans can monitor immunotherapy treatment for metastatic melanoma and predict outcome, allowing personalized therapy adjustments. The study demonstrates that FDG PET/CT can accurately assess tumor response to checkpoint inhibitor therapy with ipilimumab.
A study at St. Jude Children's Research Hospital identified MAP3K8 as the most commonly mutated gene in pediatric spitzoid melanoma, driving cancer growth and treatment response. Comprehensive genomic testing revealed novel mutations, including kinase fusions, that may be targeted by precision medicines.
Researchers found that a single dose of PD-1 inhibitor before surgery can lead to complete remission and cancer-free follow-up for more than two years. Immune responses from this therapy can peak within seven days, allowing for earlier guidance on the most effective treatment approach.
A new study by Cancer Research UK found that smokers with melanoma are 40% less likely to survive than non-smokers. Researchers believe smoking may disrupt the immune system's ability to fight cancer.
Researchers sequenced the genomes of human, canine, and equine mucosal melanoma tumours to identify key genes driving the disease. The study reveals genetic similarities between species, shedding light on why immunotherapies are ineffective for some patients with this rare type of cancer.
A recent study discovered similar genetic mutations in humans, dogs, and horses that could lead to new drug targets for a rare form of melanoma. The research compared cancer genomes across species to pinpoint key genes mutated in mucosal melanoma.
A new PET probe targets melanin pigment in skin cancer lesions to improve detection of primary and metastatic melanoma. The probe shows promising results in clinical trials, outperforming existing methods like 18F-FDG PET/CT scans.
A state-by-state analysis reveals that melanoma survival rates differ substantially across the US, with states having more practicing physicians and higher percentage of Caucasians experiencing lower survival rates. The study highlights the need for targeted approaches to improve care and reduce deaths associated with melanoma.
A comprehensive study reveals that p62 protein controls multiple factors involved in melanoma metastasis, indicating a coordinated process. The research also identifies FERMT2 as a marker for poor patient prognosis.